Diamyd Medical Equity 2024

Diamyd Medical Aktienanalyse

What does Diamyd Medical do?

Diamyd Medical AB is a Swedish company specializing in the development of therapies for the treatment of autoimmune diseases, particularly type 1 diabetes. The company was founded in 1996 and is headquartered in Stockholm. It commercialized the discovery of Professor Johnny Ludvigsson at Linköping University, who developed a therapy based on the substance GAD (Glutamate Decarboxylase). The company has developed its own GAD-based product called Diamyd®, which is an injection solution that targets the patient's immune system to protect insulin production. In addition to Diamyd®, the company has developed other products based on similar active ingredients, the most important being Remygen®, which combines insulin and GAD to promote insulin production. Diamyd Medical has a broad portfolio of patents and licenses to protect its intellectual property and improve its technologies. The company collaborates closely with other researchers and industry stakeholders to develop and test new therapeutic approaches. Its business model involves licensing its products to pharmaceutical companies and other partners, who then assume responsibility for clinical development and marketing while Diamyd Medical focuses on research and development of new products. The company has expanded into other areas of medicine, including cancer immunotherapy, neurology, and cell therapy. It is currently working on a promising new technology that utilizes Treg cells (regulatory T cells) for the treatment of autoimmune diseases. Diamyd Medical is well-positioned to further expand its market position and drive the development of new therapies. Diamyd Medical ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Equity Details

Analyzing Diamyd Medical's Equity

Diamyd Medical's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Diamyd Medical's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Diamyd Medical's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Diamyd Medical's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Diamyd Medical’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Diamyd Medical Stock

What is the equity of Diamyd Medical this year?

Diamyd Medical has equity of 169.4 M SEK this year.

What was the equity of Diamyd Medical compared to the previous year?

The equity of Diamyd Medical has increased/decreased by -20.98% decreased compared to the previous year.

What impact does a high equity have on investors of Diamyd Medical?

A high equity is advantageous for investors of Diamyd Medical as it is an indicator of the company's financial stability and its ability to manage risks and challenges.

What impact does low equity have on investors of Diamyd Medical?

A low equity can be a risk for investors of Diamyd Medical, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.

How does an increase in equity of Diamyd Medical affect the company?

An increase in equity of Diamyd Medical can strengthen the company's financial position and improve its ability to make investments in the future.

How does a reduction in the equity of Diamyd Medical affect the company?

A reduction in equity of Diamyd Medical can affect the financial situation of the company and lead to a higher dependence on debt capital.

What are some factors that influence the equity of Diamyd Medical?

Some factors that can affect the equity of Diamyd Medical include profits, dividend payments, capital increases, and acquisitions.

Why is the equity of Diamyd Medical so important for investors?

The equity of Diamyd Medical is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.

What strategic measures can Diamyd Medical take to change the equity?

To change equity, Diamyd Medical can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.

How much dividend does Diamyd Medical pay?

Over the past 12 months, Diamyd Medical paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Diamyd Medical is expected to pay a dividend of 0 SEK.

What is the dividend yield of Diamyd Medical?

The current dividend yield of Diamyd Medical is .

When does Diamyd Medical pay dividends?

Diamyd Medical pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Diamyd Medical?

Diamyd Medical paid dividends every year for the past 0 years.

What is the dividend of Diamyd Medical?

For the upcoming 12 months, dividends amounting to 0 SEK are expected. This corresponds to a dividend yield of 0 %.

In which sector is Diamyd Medical located?

Diamyd Medical is assigned to the 'Health' sector.

Wann musste ich die Aktien von Diamyd Medical kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Diamyd Medical from 6/19/2024 amounting to 0 SEK, you needed to have the stock in your portfolio before the ex-date on 6/19/2024.

When did Diamyd Medical pay the last dividend?

The last dividend was paid out on 6/19/2024.

What was the dividend of Diamyd Medical in the year 2023?

In the year 2023, Diamyd Medical distributed 0 SEK as dividends.

In which currency does Diamyd Medical pay out the dividend?

The dividends of Diamyd Medical are distributed in SEK.